Back to search

Article

BT-11 repurposing potential for Alzheimer’s disease and insights into its mode of actions

2024-10-29

Abstract excerpt

Neuroinflammation is a key pathological hallmark of Alzheimer’s disease (AD). Investigational and FDA approved drugs targeting inflammation already exist, thus drug repurposing for AD is a suitable approach. BT-11 is an investigational drug that reduces inflammation in the gut and improves cognitive function. BT-11 is orally active and binds to lanthionine synthetase C-like 2 (LANCL2), a glutathione-s-transferase,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c7dc9ecd-838f-5829-8bec-546b93367870
DOI
10.1101/2024.10.29.620882
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
BT-11 repurposing potential for Alzheimer’s disease and insights into its mode of actionsDOI 10.1101/2024.10.29.620882
Epigenetic Regulation of Neuroinflammation Leading to Dementia of Alzheimer’s Disease and Other Forms of DementiasSemantic proximity
PTAFR Exaggerates Microglia-Mediated Microenvironment via IL10-STAT3 Signaling: A Novel Perspective on Potential Biomarker and Target for AD Diagnosis and TreatmentSemantic proximity
Liver-X receptor β-selective agonist CE9A215 regulates Alzheimer’s disease- associated pathology in a 3xTg-AD mouse modelSemantic proximity
Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.Semantic proximity
A meta-analysis of bulk RNA-seq datasets identifies potential biomarkers and repurposable therapeutics against Alzheimer’s diseaseSemantic proximity
Exploring the therapeutic potential of natural compounds for Alzheimer's disease: Mechanisms of action and pharmacological propertiesSemantic proximity
Molecular Targets in Alzheimer’s Disease: From Pathogenesis to TherapeuticsSemantic proximity
SIRT2 as a potential new therapeutic target for Alzheimer’s diseaseSemantic proximity
Next-generation neurotherapeutics: nanotechnology, immunotherapy, and gene editing for neurodegenerative diseasesSemantic proximity
LAX1 as a Core Biomarker in Alzheimer's Disease and Periodontitis via the STAT signaling pathwaySemantic proximity
An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s diseaseSemantic proximity
Plasmalogen-Independent Neuroprotection: Synthetic alkyl ether lipids activate signaling to mitigate neuroinflammation and enhance cognitive functionSemantic proximity
Select a neighboring publication to make it the new centre.